NASH | Non-alcoholic Steatohepatitis Market
Nonalcoholic fatty liverdisease (NAFLD) is a disease which is a result of the accumulation of
excess fat in the liver in people who drink little to no alcohol.
There exist two types of NAFLD,
one being simple fatty liver and the other one being Nonalcoholic Steatohepatitis
(NASH).
Simple fatty liver, aka
nonalcoholic fatty liver (NAFL), is a condition in which fat deposition is in
the liver without any noticeable inflammation of liver cells.
On the other hand, in case of NASH
there is severe inflammation and damage of the liver cell, along with the
excess of in the liver. It can lead to fibrosis, scarring, cirrhosis of the
liver, and in serious cases liver cancer.
It is the most common form of
chronic liver disease, affecting about one-quarter of the population. Most
people with NAFLD have simple fatty liver. Only a small number of people with
NAFLD have NASH. Experts estimate that about 20 percent of people with NAFLD
have NASH.
Obesity is associated with a
spectrum of fatty liver diseases like nonalcoholic fatty liver disease (NAFLD).
According to DelveInsight, an increase in obesity, diabetes population will
significantly increase the prevalent cases of NAFLD with the CAGR of 1.02% for
the study period i.e. 2017–2028 in the 7MM.
The NASH treatment market is
highly dependent on off-label therapies. Due to the paucity of the standard
therapies, certain supportive therapy regimen is adopted along with the
suggested lifestyle modifications.
The market for the treatment of
Nonalcoholic Steatohepatitis (NASH) is likely to experience significant annual
growth over the 2017–2028 study period, as major-market sales are expected to
increase by 2028.
As the number of effective treatments
for the NASH increases during the forecast period [2019–2028], the supportive
therapies (off-label) market share will also start to decrease, from a peak of
100% in 2017 to ~ 11% in 2028.
Due to the huge unmet need of
such a prevalent devastating disease, researchers and scientist are vigorously
working on finding a therapy that can target NASH solely.
As per DelveInsight’s analysts,
upcoming drugs will positively impact the NASH market.
Key players in the NASH market
are Genfit, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira
Therapeutics), Galmed Pharmaceuticals, Bristol-Myers Squibb, Cirius
Therapeutics, Conatus Pharmaceuticals, Galectin Therapeutics, Immuron, NGM
Biopharmaceuticals, Akcea Therapeutics, and others.
Plausible Challenges
Pharma companies are struggling to dominate the NASH market. The launch
of emerging therapies is anticipated to further accelerate the NASH market.
Regulatory organizations like FDA and several others are helping in
strengthening of the late-stage pipeline of NASH by easing the guidelines for
approval.
Moreover, the increasing prevalence, awareness of the disease, and
promising emerging pipeline herapies
will fuel the NASH market size in the future.
Water Hack Burns 2 lb of Fat OVERNIGHT
ReplyDeleteWell over 160 000 women and men are utilizing a easy and secret "liquid hack" to lose 2 lbs each and every night as they sleep.
It's simple and it works every time.
Just follow these easy step:
1) Hold a drinking glass and fill it with water half the way
2) And then use this awesome HACK
you'll be 2 lbs skinnier when you wake up!